A nutrient-dense fruit whose most consistent effect is lowering total and "bad" cholesterol and blood fats while modestly raising "good" cholesterol; it may also lower blood sugar, ease inflammation, and improve the blood-vessel lining. Generally very well tolerated, with mild digestive upset most common. A low-risk botanical with promising but not yet settled heart and metabolic support. (Full Review)
| Marker | Target | Why |
|---|---|---|
| LDL cholesterol | < 100 mg/dL | Primary target of amla's lipid effect |
| Total cholesterol | < 180 mg/dL | Broad lipid overview and trial endpoint |
| Triglycerides | < 90 mg/dL | Blood fats responsive to amla |
| HDL cholesterol | > 55 mg/dL (men), > 60 (women) | May rise modestly with amla |
| Fasting blood glucose | 75–90 mg/dL | Tracks glycemic effect and hypoglycemia risk |
| HbA1c | < 5.4% | Average blood sugar over ~3 months |
| hs-CRP | < 1.0 mg/L | Tracks the anti-inflammatory effect |
| ALT / AST (liver enzymes) | ALT < 25 U/L (men), < 20 (women) | General safety and metabolic-liver context |
Cadence: Recheck lipid panel and fasting glucose at 8–12 weeks, then every 6–12 months; check glucose more often in the first weeks if on diabetes medication.